A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

The safety and tolerability as assessed by adverse events, vital signs, 12-lead electrocardiograms and laboratory assessments.

Time frame: up to 48 weeks

The proportion of subjects who have an SVR 24 weeks after the last planned dose of the study drug (SVR24)

Time frame: 24 weeks

The proportion of subjects who achieve undetectable HCV RNA at Weeks 2, 4, 8, and 12 after the first dose of study drug, and at the end of planned study drug treatment

Time frame: up to week 12

The proportion of subjects who have on-treatment virologic failure defined as subjects who either meet a futility rule or who complete the assigned treatment duration and have HCV RNA at the end of study drug treatment

Time frame: up to 48 weeks

The association of the IL-28B genotype with SVR12

Proportion of subjects who have SVR12 by IL-28B genotype

Time frame: 12 weeks

The amino acid sequence of the nonstructural (NS)3 and NS5B proteins in subjects who have treatment failure

The identity and observed frequency of viral variants as compared to wild-type virus will be measured.

Time frame: After the last planned dose of study drug or after time of failure

VX-222, telaprevir, and RBV plasma concentrations and Peg-IFN serum concentrations

Time frame: 12 weeks